Addition of bevacizumab to compensate for the negative influence of attenuated relative dose intensity of cytotoxic agents on the outcome in patients with metastatic colorectal cancer.
Goro Nakayama
No relevant relationships to disclose
Naomi Hayashi
No relevant relationships to disclose
Chie Tanaka
No relevant relationships to disclose
Tsutomu Fujii
No relevant relationships to disclose
Yuichi Ando
No relevant relationships to disclose
Yasuhiro Kodera
No relevant relationships to disclose